JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Organizace: ULTIMATE I and ULTIMATE II Investigators

1 záznamů v Medvik Filtry

Článek online

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Steinman, Lawrence
Autor Steinman, Lawrence From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Fox, Edward
Autor Fox, Edward From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Hartung, Hans-Peter
Autor Hartung, Hans-Peter From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Alvarez, Enrique
Autor Alvarez, Enrique From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Qian, Peiqing
Autor Qian, Peiqing From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Wray, Sibyl
Autor Wray, Sibyl From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Robertson, Derrick
Autor Robertson, Derrick From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Huang, DeRen
Autor Huang, DeRen From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Selmaj, Krzysztof
Autor Selmaj, Krzysztof From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)
Wynn, Daniel
Autor Wynn, Daniel From the Beckman Center for Molecular Medicine, Stanford University, Stanford (L.S.), and the Weill Institute for Neurosciences, University of California, San Francisco, San Francisco (B.A.C.C.) - both in California Central Texas Neurology Consultants, Round Rock (E.F.) Heinrich Heine University Medical School, Düsseldorf, Germany (H.-P.H.) the Brain and Mind Centre, University of Sydney, Sydney (H.-P.H.) Medical University of Vienna, Vienna (H.-P.H.) Palacký University Olomouc, Olomouc, Czech Republic (H.-P.H.) University of Colorado, Aurora (E.A.) Swedish Medical Center, Seattle (P.Q.) Hope Neurology, Knoxville, TN (S.W.) University of South Florida, Tampa (D.R.) Columbus Neuroscience, Westerville, OH (D.H.) the Department of Neurology, University of Warmia and Mazury, Olsztyn, and Center of Neurology, Lodz - both in Poland (K.S.) Consultants in Neurology, Northbrook, IL (D.W.) and TG Therapeutics, New York (G.C., K.M., Y.H., Y.X., M.S.W., J.A.B., S.A.P., L.L., H.P.M.)

The New England journal of medicine. 2022 ; 387 (8) : 704-714. [pub] 20220825

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis. METHODS: In two identical, phase 3, double-blind, double-dummy trials (ULTIMATE I and II), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive intravenous ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72) and oral placebo or oral teriflunomide (14 mg once daily) and intravenous placebo. The primary end point was the annualized relapse rate. Secondary end points included the number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) by 96 weeks and worsening of disability. RESULTS: A total of 549 participants were enrolled in the ULTIMATE I trial, and 545 were enrolled in the ULTIMATE II trial; the median follow-up was 95 weeks. In the ULTIMATE I trial, the annualized relapse rate was 0.08 with ublituximab and 0.19 with teriflunomide (rate ratio, 0.41; 95% confidence interval [CI], 0.27 to 0.62; P<0.001); in the ULTIMATE II trial, the annualized relapse rate was 0.09 and 0.18, respectively (rate ratio, 0.51; 95% CI, 0.33 to 0.78; P = 0.002). The mean number of gadolinium-enhancing lesions was 0.02 in the ublituximab group and 0.49 in the teriflunomide group (rate ratio, 0.03; 95% CI, 0.02 to 0.06; P<0.001) in the ULTIMATE I trial and 0.01 and 0.25, respectively (rate ratio, 0.04; 95% CI, 0.02 to 0.06; P<0.001), in the ULTIMATE II trial. In the pooled analysis of the two trials, 5.2% of the participants in the ublituximab group and 5.9% in the teriflunomide group had worsening of disability at 12 weeks (hazard ratio, 0.84; 95% CI, 0.50 to 1.41; P = 0.51). Infusion-related reactions occurred in 47.7% of the participants in the ublituximab group. Serious infections occurred in 5.0% in the ublituximab group and in 2.9% in the teriflunomide group. CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. Ublituximab was associated with infusion-related reactions. (Funded by TG Therapeutics; ULTIMATE I and II ClinicalTrials.gov numbers, NCT03277261 and NCT03277248.).

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH